Patent ID: 6030812
Filing Date: 2000-02-29
Classification: A61K,A61P,C07K

Abstract:
A fusion protein comprising; a modified human interleukin-3 (hIL-3) amino acid sequence, wherein said modified sequence differs from the sequence of native (1-133) human IL-3 by the replacement of from 4 to about 44 of the residues corresponding to positions 17-118 of native (1-133) hIL-3 by other amino acids, with the proviso that the residues corresponding to positions 101 or 116 are not Ala or Val, respectively; and with the proviso that no more than one of the amino acids at positions 63, 82, 87, 98, and 112 are different from the corresponding amino acids in native human interleukin-3; wherein optionally said modified sequence further differs from the sequence of native (1-133) hIL-3 by the deletion of from 1 to 14 residues from the N-terminus of native (1-133) hIL-3, the deletion of from 1 to 15 residues from the C-terminus of native (1-133) hIL-3, or both; and wherein a polypeptide having only said modified human interleukin-3 (hIL-3) amino acid sequence has increased activity relative to native human interleukin-3, in at least one assay selected from the group consisting of: AML cell proliferation, TF-1 cell proliferation and Methylcellulose assay.